{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:17:49Z","timestamp":1722889069074},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00393-013-1318-3","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T06:33:28Z","timestamp":1396420408000},"page":"287-289","source":"Crossref","is-referenced-by-count":1,"title":["Empfehlungen zum Einsatz von Rituximab bei ANCA-assoziierten Vaskulitiden","Recommendations on the use of rituximab for ANCA-associated vasculitis"],"prefix":"10.1007","volume":"73","author":[{"name":"Kommission f\u00fcr Pharmakotherapie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Gause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. N Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"1318_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"1318_CR3","unstructured":"Open drug database. http:\/\/ch.oddb.org\/de\/gcc\/fachinfo\/reg\/54378. Zugegriffen: 15.01.2014"},{"key":"1318_CR4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-201405","volume":"72","author":"Terrier","year":"2013","unstructured":"Terrier B, Pagnoux C, Karras A et al (2013) Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies ANCA-associated vasculitis (MAINRITSAN): foffow up at 34 months. Ann Rheum Dis 72(Suppl 3):124","journal-title":"Ann Rheum Dis"},{"key":"1318_CR5","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center. Arthritis Rheum 64:3770\u20133778","journal-title":"Arthritis Rheum"},{"key":"1318_CR6","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ et al (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760\u20133769","journal-title":"Arthritis Rheum"},{"key":"1318_CR7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417\u2013427","journal-title":"N Engl J Med"},{"key":"1318_CR8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","volume":"63","author":"Knight","year":"2004","unstructured":"Knight A, Askling J, Granath F et al (2004) Urinary bladder cancer in Wegener\u2019s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63:1307\u20131311","journal-title":"Ann Rheum Dis"},{"key":"1318_CR9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"Travis","year":"1995","unstructured":"Travis LB, Curtis RE, Glimelius B et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma. J Natl Cancer Inst 87:524\u2013530","journal-title":"J Natl Cancer Inst"},{"key":"1318_CR10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00393-012-0982-z","volume":"71","author":"Holle","year":"2012","unstructured":"Holle JU, Reinhold-Keller E, Gross WL (2012) Update on granulomatosis with polyangitis (GPA, Wegener\u2019s granulomatosis). Z Rheumatol 71:745\u2013753","journal-title":"Z Rheumatol"},{"key":"1318_CR11","doi-asserted-by":"crossref","unstructured":"Moosig F, Holle JU, Gross WL (2009) Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS. Internist (Berl) 50:298\u2013309","DOI":"10.1007\/s00108-008-2251-4"},{"key":"1318_CR12","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A (2014) Empfehlungen zum Einsatz von Rituximab bei Patienten mit rheumatoider Arthritis. Z Rheumatol (im Druck)","DOI":"10.1007\/s00393-013-1238-2"},{"key":"1318_CR13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","volume":"34","author":"Martinez","year":"2009","unstructured":"Martinez Del PM, Chaudhry A, Jones RB et al (2009) B-cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: a cohort study. Clin Otolaryngol 34:328\u2013335","journal-title":"Clin Otolaryngol"},{"key":"1318_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","volume":"41","author":"Vananuvat","year":"2011","unstructured":"Vananuvat P, Suwannalai P, Sungkanuparph S et al (2011) Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41:497\u2013502","journal-title":"Semin Arthritis Rheum"},{"key":"1318_CR15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310\u2013317","journal-title":"Ann Rheum Dis"},{"key":"1318_CR16","unstructured":"Birmingham-Vaskulitis-Aktivit\u00e4ts-Score. http:\/\/dgrh.de\/rheumadok.html. http:\/\/vasculitis.org\/images\/documents\/bvas_v3.0.pdf. Zugegriffen: 15.01.2014"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1318-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1318-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:17Z","timestamp":1559046977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1318-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1318-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}